If adverse drug reactions occur, contact your healthcare professional, pharmacist, or directly to the information database on adverse drug reactions (actions), including reports of drug ineffectiveness RSE on REM National Center for Expertise of Medicines and Medical Devices of the Committee for Medical and Pharmaceutical Control of the Ministry of Health of the Republic of Kazakhstan additional information Composition of the medicinal product One bottle contains: active substance: reduced glutathione sodium salt 0.646 g, corresponds to 600 mg reduced glutathione one ampoule with solvent contains: water for injection Release form and packaging 0.646 g of the drug is placed in a transparent glass bottle, sealed with a rubber stopper and sealed with an aluminum cap
Maintain aseptic technique throughout
Disorder of Glutathione Metabolism
Schisano B, Harte AL, Lois K, Saravanan P, Al-Daghri N, Al-Attas O, Knudsen LB, McTernan PG, Ceriello A, Tripathi G: GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress